Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study

OBJECTIVE: To compare clinical effectiveness between tocilizumab and tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and inadequate response to conventional synthetic disease‐modifying antirheumatic drugs initiating biologic therapy. METHODS: Patients prescribed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, Ernest H., Bernasconi, Corrado, Aassi, Maher, Molina, Jose Fernando, Epis, Oscar Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656814/
https://www.ncbi.nlm.nih.gov/pubmed/28622454
http://dx.doi.org/10.1002/acr.23303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656814/
https://www.ncbi.nlm.nih.gov/pubmed/28622454
http://dx.doi.org/10.1002/acr.23303

Ejemplares similares